De Novo device
DuraGraft Vascular Conduit Solution
Marizyme · Flushing Solution For Short Term Storage Of Veins At Room Temperature During Coronary Artery Bypass Graft Surgeries (QEJ, Class II) · First FDA decision Oct 4, 2023, newest May 1, 2024Coronary artery disease
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
1
Naming "DuraGraft"
MAUDE reports
0
Brand "DuraGraft", since 2015
PubMed studies
21
Mentioning "DuraGraft"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing DuraGraft Vascular Conduit Solution
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K240925 · Decided May 1, 2024 · 27 days after receipt
Device type: Flushing Solution For Short Term Storage Of Veins At Room Temperature During Coronary Artery Bypass Graft Surgeries (QEJ) · GI, Urology & Nephrology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "DuraGraft", any status and sponsor, newest update first.
- EU Multicenter Registry to Assess Outcomes in CABG Patients: Treatment of Vascular Conduits With DuraGraft [VASC]Status unknown
Somahlution LLCNot on our public-company list
NCT02922088 · 2,964 participants · Start Dec 9, 2016 · Primary completion Aug 2024
Device: DuraGraft · For: Cardiovascular Diseases; Coronary Artery Disease
Sites: Vienna, Austria; Aachen, Germany; Berlin, Germany · 36 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "DuraGraft", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QEJ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "DuraGraft"[tiab]. The summary above synthesizes these.
- Specific Graft Treatment Solution Enhances Vascular Endothelial Function.
Kiss A, Szabo PL, Dostal C, et al. · Rev Cardiovasc Med · 2022
- Intraoperative storage of saphenous vein grafts in coronary artery bypass grafting.
Pachuk CJ, Rushton-Smith SK, Emmert MY · Expert Rev Med Devices · 2019
- Sequential multidetector computed tomography assessments after venous graft treatment solution in coronary artery bypass grafting.
Perrault LP, Carrier M, Voisine P, et al. · J Thorac Cardiovasc Surg · 2021
- Clinical outcomes and quality of life after contemporary isolated coronary bypass grafting: a prospective cohort study.
Sandner S, Misfeld M, Caliskan E, et al. · Int J Surg · 2023Multicenter Study
- Efficacy of Intraoperative Vein Graft Storage Solutions in Preserving Endothelial Cell Integrity during Coronary Artery Bypass Surgery.
Toto F, Torre T, Turchetto L, et al. · J Clin Med · 2022
- Long-term outcomes of venous graft preservation in a rat autologous transplant model.
Santander MJ, Mardus A, Kensah G, et al. · Sci Rep · 2026Research Support, Non-U.S. Gov't
- In a rat model of bypass DuraGraft ameliorates endothelial dysfunction of arterial grafts.
Lian S, Loganathan S, Mayer T, et al. · Sci Rep · 2024
- Comparison of storage solutions on saphenous vein endothelial function using immunofluorescence. A pilot study.
Danby A, Briffa N · Perfusion · 2024
- Outcomes after surgical revascularization in diabetic patients.
Misfeld M, Sandner S, Caliskan E, et al. · Interdiscip Cardiovasc Thorac Surg · 2024
- Graft Preservation Solution DuraGraft® Alleviates Vascular Dysfunction Following In Vitro Ischemia/Reperfusion Injury in Rats.
Korkmaz-Icöz S, Ballikaya B, Soethoff J, et al. · Pharmaceuticals (Basel) · 2021
- Effect of different storage solutions on oxidative stress in human saphenous vein grafts.
Tekin I, Demir M, Özdem S · J Cardiothorac Surg · 2022
- The Role of Preservation Solutions upon Saphenous Vein Endothelial Integrity and Function: Systematic Review and UK Practice Survey.
Layton GR, Ladak SS, Abbasciano R, et al. · Cells · 2023Systematic Review, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.